secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2025-06-13T23:59:59+00:00
Accession:  0001104659-25-059435
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma shareholders elect director, ratify auditor at 2025 annual meeting
--------------------------------------------------------------------------------

- Quorum of 14,605,167 shares (61.86%) present out of 23,606,443 outstanding shares.
- Class III director James Oliviero elected with 9,882,555 votes for, 240,327 against, 782 abstentions.
- Ratification of Kesselman & Kesselman as independent auditor approved with 14,561,983 votes for, 40,324 against.
- All proposals passed as detailed in the April 28, 2025 proxy statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465925059435/0001104659-25-059435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465925059435/tm2518009d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-059435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer